RPTX Repare Therapeutics
- 3.270
- -0.130-3.82%
Repare Therapeutics News
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation
Repare Therapeutics Analyst Ratings
Buy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Ahead
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Repare Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $10
Repare Therapeutics Analyst Ratings
Piper Sandler Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Buy Rating on Repare Therapeutics: Solid Financials and Promising Oncology Pipeline Despite Roche Setback
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Repare Therapeutics (RPTX)
Repare Therapeutics (RPTX) Has a New Rating From Piper Sandler
Repare Therapeutics' Promising Partnerships and Pipeline Propel Buy Rating
Repare Therapeutics' Promising New Programs and Key Milestones: A Buy Rating Analysis
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $25 Price Target
Repare Therapeutics Analyst Ratings
Promising Preclinical Data and Potential for Addressing Unmet Need Drive Buy Rating for Repare Therapeutics
TD Cowen Analyst Assigns Buy Rating to Repare Therapeutics, Anticipates Promising Results From Lunresertib Trials Despite Anemia Concerns
Repare Therapeutics: Competitive Edge and Upcoming Catalysts Drive Buy Rating
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Repare Therapeutics (RPTX)
Analysis
Price Target
No Data
